Logo image of RAPT

RAPT THERAPEUTICS INC (RAPT) Stock Fundamental Analysis

USA - NASDAQ:RAPT - US75382E2081 - Common Stock

28.85 USD
+1.06 (+3.81%)
Last: 11/14/2025, 8:19:49 PM
28.85 USD
0 (0%)
After Hours: 11/14/2025, 8:19:49 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RAPT. RAPT was compared to 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RAPT as it has an excellent financial health rating, but there are worries on the profitability. RAPT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RAPT had negative earnings in the past year.
In the past year RAPT has reported a negative cash flow from operations.
RAPT had negative earnings in each of the past 5 years.
In the past 5 years RAPT always reported negative operating cash flow.
RAPT Yearly Net Income VS EBIT VS OCF VS FCFRAPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

RAPT has a Return On Assets of -63.74%. This is comparable to the rest of the industry: RAPT outperforms 40.87% of its industry peers.
The Return On Equity of RAPT (-69.51%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -63.74%
ROE -69.51%
ROIC N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
RAPT Yearly ROA, ROE, ROICRAPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RAPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPT Yearly Profit, Operating, Gross MarginsRAPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, RAPT has more shares outstanding
RAPT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RAPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RAPT Yearly Shares OutstandingRAPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
RAPT Yearly Total Debt VS Total AssetsRAPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 13.23 indicates that RAPT is not in any danger for bankruptcy at the moment.
RAPT's Altman-Z score of 13.23 is amongst the best of the industry. RAPT outperforms 86.44% of its industry peers.
There is no outstanding debt for RAPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.23
ROIC/WACCN/A
WACCN/A
RAPT Yearly LT Debt VS Equity VS FCFRAPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RAPT has a Current Ratio of 12.04. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 12.04, RAPT belongs to the best of the industry, outperforming 85.88% of the companies in the same industry.
A Quick Ratio of 12.04 indicates that RAPT has no problem at all paying its short term obligations.
RAPT has a Quick ratio of 12.04. This is amongst the best in the industry. RAPT outperforms 85.88% of its industry peers.
Industry RankSector Rank
Current Ratio 12.04
Quick Ratio 12.04
RAPT Yearly Current Assets VS Current LiabilitesRAPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.09% over the past year.
EPS 1Y (TTM)50.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RAPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.14% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.72%
EPS Next 2Y35.94%
EPS Next 3Y22.32%
EPS Next 5Y11.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPT Yearly Revenue VS EstimatesRAPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2030 2031 2032 200M 400M 600M
RAPT Yearly EPS VS EstimatesRAPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RAPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RAPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPT Price Earnings VS Forward Price EarningsRAPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPT Per share dataRAPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

RAPT's earnings are expected to grow with 22.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.94%
EPS Next 3Y22.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RAPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPT THERAPEUTICS INC

NASDAQ:RAPT (11/14/2025, 8:19:49 PM)

After market: 28.85 0 (0%)

28.85

+1.06 (+3.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners82.07%
Inst Owner Change-1.01%
Ins Owners0.42%
Ins Owner Change0%
Market Cap477.18M
Revenue(TTM)N/A
Net Income(TTM)-105.64M
Analysts81.25
Price Target57.12 (97.99%)
Short Float %4.12%
Short Ratio1.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.19%
Min EPS beat(2)0.82%
Max EPS beat(2)31.56%
EPS beat(4)3
Avg EPS beat(4)-31.54%
Min EPS beat(4)-200.44%
Max EPS beat(4)41.9%
EPS beat(8)7
Avg EPS beat(8)-11.46%
EPS beat(12)9
Avg EPS beat(12)-7.23%
EPS beat(16)13
Avg EPS beat(16)-3.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)131.72%
PT rev (3m)115.39%
EPS NQ rev (1m)6.14%
EPS NQ rev (3m)-16.39%
EPS NY rev (1m)17.61%
EPS NY rev (3m)-6.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.14
P/tB 3.14
EV/EBITDA N/A
EPS(TTM)-11.06
EYN/A
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)-5.24
FCFYN/A
OCF(TTM)-5.23
OCFYN/A
SpS0
BVpS9.19
TBVpS9.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.74%
ROE -69.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.04
Quick Ratio 12.04
Altman-Z 13.23
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)61.2%
Cap/Depr(5y)59.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.71%
EPS Next Y87.72%
EPS Next 2Y35.94%
EPS Next 3Y22.32%
EPS Next 5Y11.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.29%
EBIT Next 3Y-4.93%
EBIT Next 5YN/A
FCF growth 1Y7.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.03%
OCF growth 3YN/A
OCF growth 5YN/A

RAPT THERAPEUTICS INC / RAPT FAQ

What is the fundamental rating for RAPT stock?

ChartMill assigns a fundamental rating of 3 / 10 to RAPT.


What is the valuation status of RAPT THERAPEUTICS INC (RAPT) stock?

ChartMill assigns a valuation rating of 1 / 10 to RAPT THERAPEUTICS INC (RAPT). This can be considered as Overvalued.


Can you provide the profitability details for RAPT THERAPEUTICS INC?

RAPT THERAPEUTICS INC (RAPT) has a profitability rating of 1 / 10.